Hundreds of people gathered in Dublin city center to protest as the Health Service Executive (HSE) prepares to make a final decision on whether to fund the drug Skyclarys for patients with Friedreich's Ataxia. The demonstration, which took place over several days, saw participants holding signs and chanting as they called for the HSE to approve reimbursement for the treatment.
Studies suggest Skyclarys could slow the progression of Friedreich's Ataxia by up to 50%, making it a critical option for those living with the condition. Patients and advocates argue that the treatment is both effective and necessary, yet funding remains uncertain. The HSE is set to announce its decision within days, leaving families in limbo.
The protest reflects growing frustration among patients and their families, who have been waiting for a decision for months. Advocacy groups have emphasized the importance of timely access to the drug, highlighting its potential to improve quality of life. As the deadline approaches, the pressure on the HSE to act remains intense.
The situation underscores the challenges faced by patients with rare diseases in securing essential treatments. With no clear timeline for a decision, the community continues to demand action.
